News from Synapse Biomedical Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 17, 2016, 05:00 ET French Study Of NeuRx® Diaphragm Pacing System (DPS) In Off-Label ALS Patients Confirms: NeuRx DPS® Should Be Used With NIV In Later Stage Of Disease

Synapse Biomedical Inc. (www.synapsebiomedical.com) announced that the results of a small French trial (RespiStimALS), designed to assess the...


Oct 04, 2016, 18:52 ET New ALS Device Trial; the PARADIGM Study Will Continue Research of the NeuRx® Diaphragm Pacing System (DPS) in ALS Patients

 Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today that it will be rolling out a new ALS trial for its NeuRx Diaphragm Pacing...


Aug 23, 2016, 07:30 ET Novel Technology for Veterans with Spinal Cord Injury or ALS to be presented at this year's Paralyzed Veterans of America (PVA) Summit in Orlando: NeuRx® Diaphragm Pacing System (DPS) Shows Benefit In SCI and ALS Patients

Synapse Biomedical (www.synapsebiomedical.com )  announced today, Dr. Raymond Onders, co-inventor of the NeuRx® Diaphragm Pacing System...


Aug 09, 2016, 07:30 ET Synapse Biomedical, Inc. Awarded GSA Schedule for NeuRx® Diaphragm Pacing System product line; device will benefit veterans with spinal cord injury (SCI) and ALS

Synapse Biomedical (www.synapsebiomedical.com ) has been awarded a GSA Schedule 65IIA contract and is now certified to provide goods & services...


Apr 26, 2016, 17:40 ET Long-Term Follow Up Study Reports An Overwhelming Majority Of Patients Pleased With Diaphragm Pacing

 Results of a long-term follow up study on patients with spinal cord injuries implanted with the NeuRx® Diaphragm Pacing System (DPS)...


Oct 15, 2015, 10:22 ET Synapse Biomedical and Case Western Reserve University Announce Collaboration to Commercialize Advanced Neurostimulation Technology

With the support of a $3 million Ohio Third Frontier Innovation Platform Program grant, Synapse Biomedical Inc. will lead the commercialization of...


Oct 13, 2015, 12:42 ET U.S. Diaphragm Pacing Study in ALS Continues Enrollment: The Post Approval Study's (PAS) Interim Data Showed Device Safety and Median Survival Post-Implant of 20.9 months

 Synapse Biomedical Inc. (www.synapsebiomedical.com) reported today that the U.S. multi-center, Post Approval Study (PAS) studying the use of...


Sep 30, 2014, 08:30 ET Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients

 Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has completed the enrollment of the post-approval study of its NeuRx...


Dec 18, 2013, 14:52 ET Synapse Biomedical Receives $2.4 Million

Supports Next Generation of NeuRx® Platform  Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has been awarded...


Nov 13, 2013, 13:00 ET Synapse Biomedical Receives Canadian Health Ministry Approval of NeuRx Diaphragm Pacing System (DPS)® For Spinal Cord Injury Breathing Applications

 Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has received approval from the Health Canada for its NeuRx DPS®...


Sep 30, 2011, 16:04 ET Synapse Biomedical obtient l'approbation de la FDA pour le système d'entrainement de diaphragme NeuRx (DPS)® pour traiter la sclérose latérale amyotrophique (SLA)

Synapse Biomedical, Inc. a annoncé que la U.S. Food and Drug Administration (FDA) avait approuvé le Système d'entrainement de...


Sep 30, 2011, 14:44 ET Synapse Biomedical erhält FDA-Zulassung für das NeuRx Diaphragm Pacing System (DPS)® bei der Behandlung von Amyotropher Lateralsklerose (ALS)

Synapse Biomedical, Inc. gab heute bekannt, die US-Arzneimittelbehörde (FDA) habe das NeuRx Diaphragm Pacing System(DPS)®...


Sep 29, 2011, 14:54 ET Synapse Biomedical recibe la aprobación de la FDA para el NeuRx Diaphragm Pacing System (DPS)®

- Synapse Biomedical recibe la aprobación de la FDA para el NeuRx Diaphragm Pacing System (DPS)® para tratar la esclerosis lateral...


Sep 29, 2011, 09:56 ET Synapse Biomedical Receives FDA Approval for NeuRx Diaphragm Pacing System (DPS)® to Treat Amyotrophic Lateral Sclerosis (ALS)

Synapse Biomedical, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved its NeuRx Diaphragm Pacing System (DPS)® for...


Oct 08, 2010, 11:47 ET Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS)

Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm...


Jun 18, 2008, 01:00 ET Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications

CLEVELAND, June 18 /PRNewswire/ -- Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has received approval from the U.S....